Bicara Therapeutics (BCAX) Net Cash Flow (2023 - 2026)

Bicara Therapeutics has reported Net Cash Flow for 4 years, with the latest figure at $226.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 920.29% year-over-year to $226.8 million; the trailing twelve-month figure through Mar 2026 stood at -$138.6 million (down 156.34% YoY), and the FY2025 full-year result was -$393.0 million, down 251.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at $226.8 million, up from -$75.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $316.9 million in Q3 2024, with the low at -$264.9 million in Q3 2025.
• Historically, Net Cash Flow has averaged $27.9 million across 4 years, with a median of -$19.9 million in 2024.
• Annual changes were most pronounced in 2025 — Net Cash Flow slumped 183.6% — and 2026, when it jumped 920.29%.
• Bicara Therapeutics' Net Cash Flow stood at $186.2 million in 2023, then sank by 116.67% to -$31.0 million in 2024, then sank by 141.53% to -$75.0 million in 2025, then surged by 402.42% to $226.8 million in 2026.
• The last three Net Cash Flow figures came in at $226.8 million (Q1 2026), -$75.0 million (Q4 2025), and -$264.9 million (Q3 2025), per Business Quant data.